Extracorporeal Shockwave Therapy (ESWT) to Improve Function in Chronic ASIA-A Patients

Spinal Cord Injuries Clinical Trial

Official title:

Extracorporeal Shockwave Therapy (ESWT) in Patients Suffering From Complete Paraplegia at the Thoracic Level

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03399968
• Other study ID #: ESWT_SCI/1.9-2014
• Status: Recruiting
• Phase: N/A
• Start date: March 26, 2015
• Est. completion date: May 31, 2020

Study information

• Verified date: July 2019
• Source: AUVA Trauma Center Meidling
• Contact: Wolfgang Schaden, MD
• Phone: +435939320100
• Email: wolfgang.schaden[@]auva.at
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The global prevalence of spinal cord injury is estimated between 236 to 4187/Million. A spontaneous recovery of the sense-motoric function is decreasing with the time after injury and is only seen sporadically after 1 to 2 years. Treatment options are mainly limited to improvement of the quality of life.

The present prospective randomized study is intended as a double-blind, placebo controlled multi-center investigation. Patients suffering from chronic paraplegia (lesion between THII and THX, ASIA A = complete central lesion) at least for 1 year after the initial trauma without spontaneous remission of the last 6 months are considered to be included in the study. Meeting the inclusion criteria and signing the informed consent, patients are treated in one of the two study centers. At study inclusion, a baseline evaluation comprising neurological, neurophysiological, functional and clinical investigation is performed. Patients dedicated to the ESWT intervention group will be treated once a week over 6 weeks with local non-invasive low energy extracorporeal shockwave therapy (=6 treatments with an electrohydraulic device). The follow-up will include neurological, neurophysiological, clinical as well as functional evaluation at the time points 6 weeks, 3 months and 6 months. Additionally, patients will be provided with a diary for documentation of drug adaptation, grade of spasticity and pain. Those patients dedicated to the Placebo ESWT group, will receive the identical scheme in treatment (but without application of shockwaves) and follow-up as the patients in the ESWT group. However, after positive completion of the study, these patients will be offered ESWT as well.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: May 31, 2020
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients with a spinal cord injury classified as ASIA A between the level of THII to THX (complete central lesion)

• at least 1 year after trauma

• no signs of spontaneous recovery over the last 6 months

• signed informed consent

Exclusion Criteria:

• central therapies over the last 6 months (eg stem cells, electro-therapy)

• Baclofen pump

• Joint contraction lower limb > 40° (hip or knee)

• Body weight > 135 kg

• Body height > 202 cm

• non-compliant patients

• Decubital ulcers at grade II or higher

• participation in an other clinical trial within the last 6 months

• Co-morbidities which make study completion doubtful or impossible

• Additional neurological diseases which may lead to further damage to the nerval system

• Malignant tumor

Related Conditions & MeSH terms

• Spinal Cord Injuries

Intervention

Device:
• ESWT
at low energy, shockwaves are applied non-invasively at the injury level and 5 segments up and down of the spinal cord paravertebrally left and right
• Placebo ESWT
the ESWT therapy head is positioned at the level of injury and is moved up and down identically as described in the Verum intervention group (ESWT) but without application of shockwaves. The sound which is normally produced by shockwave generation is played by high quality sound recordings in the same amount as in the Verum group

Locations

Country	Name	City	State
Austria	AUVA Rehabilitation Center Tobelbad	Haselsdorf	Styria
Austria	AUVA Rehabilitation Center Weisser Hof	Klosterneuburg	Lower Austria

Sponsors (1)

Lead Sponsor	Collaborator
AUVA Trauma Center Meidling

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Motor function	Motor function of the lower limbs assessed by gait analysis tool (Lokomat (R))	24 weeks
Secondary	Sensitivity and Motor function	Assessment of levels by the ASIA score ASIA score - a neurologic assessment for patients with spinal cord injury developed by the American Spinal Injury Association.; Examination includes the pin-prick discrimination assessment at 28 specific sensory locations bilaterally but also 10 muscles bilaterally.; Sensory levels for each dermatome (nt...not testable, 0...absent sensation, 1...present sensation but impaired, 2...normal) Motor function of 5 upper extremity and 5 lower extremity key muscles (0...complete paralysis, 1...palpable or visible contraction, 2...active movement, full range of motion, gravity eliminated, 3...active movement, full range of motion, against gravity, 4...active movement, full range of motion, against gravity and provides some resistance, 5...active movement, full range of motion, against gravity and provides normal resistance, nt...not testable)	24 weeks
Secondary	Spasticity	Evaluation of spasticity degree assessed by the Tardieu test (muscle resistance to passive movement at both slow and fast speed) 2 measurements are performed: Quality of muscle reaction; Angle of muscle reaction 3 speed definitions: 1) V1 is slow as possible 2) V2 speed of limb falling under gravity 3) V3 moving as fast as possible Quality of Muscle Reaction (scored 0-5); 0 is no resistance to passive ROM to 5 indicating joint is immobile (Some versions scored 0-4).	24 weeks
Secondary	Trunk control	evaluation of trunk control by the modified functional reach test and Ott test	24 weeks
Secondary	Lung function	Assessment of lung function by peak flow measurements	24 weeks
Secondary	Quality of life	Assessed by the disability scale SCIM (spinal cord independence measure); Subscores include self-care (range von 0-20 points), respiration and sphincter management (range from 0-40), and mobility (range from 0-40); In total scale range from 0-100 (0 = total dependence, 100 = complete independence).	24 weeks